Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | DRD4 | P21917 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Reticuline SCHEMBL147596 | 1.00 | DRD2 (1.00) | DRD2DRD1BCHEACHEKCNH2 | |
| (R)-Reticuline SCHEMBL29364903 | 1.00 | DRD2 (1.00) | DRD2DRD1BCHEACHEKCNH2 | |
| (R)-Reticuline SCHEMBL9587509 | 1.00 | DRD2 (1.00) | DRD2DRD1BCHEACHEKCNH2 | |
| (S)-Reticuline SCHEMBL147597 | 1.00 | DRD2 (1.00) | DRD2DRD1BCHEACHEKCNH2 | |
| (S)-Reticuline SCHEMBL29923953 | 1.00 | DRD2 (1.00) | DRD2DRD1BCHEACHEKCNH2 | |
| Laudanidine SCHEMBL18187574 | 0.98 | DRD2 (0.95) | DRD2DRD1BCHEACHEKCNH2 | |
| Codamine SCHEMBL15696578 | 0.95 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 | |
| Codamine SCHEMBL680513 | 0.95 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 | |
| Laudanidine SCHEMBL15696580 | 0.95 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 | |
| Codamine SCHEMBL30720053 | 0.95 | DRD2 (0.91) | DRD2DRD1BCHEACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117737075-A | Enhanced expression of adeno-associated virus-delivered osteocalcin in vivo and hypoglycemic application thereof | 呈诺再生医学科技(北京)有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-117379389-A | Platelet-oncolytic virus complex, preparation method and application thereof | 四川大学 | 2024-01-12 | — | — | CN | claimed |
| WO-2023069040-A1 | USE OF RETICULIN IMPURITY AS PURITY AND STABILITY SPECIFICATION IN MORPHINE AND MORPHINE EXTRACTS | FIDAN OZAN (TR) | 2023-04-27 | — | — | WO | claimed |
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | ANTHEIA INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12416029-B2 | Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof | ANTHEIA INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250283129-A1 | PROCESS | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2025-09-11 | — | — | US | disclosed |
| CN-119955743-A | Modified oncolytic viruses, compositions and uses thereof | 上海锦斯生物技术有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119876204-A | DNA molecule for targeted degradation of target protein and application | 南开大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-113164538-B | Modified oncolytic viruses, compositions and uses thereof | 上海锦斯生物技术有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117737075-B | Enhanced expression of adeno-associated virus-delivered osteocalcin in vivo and hypoglycemic application thereof | 呈诺再生医学科技(北京)有限公司 | 2024-10-15 | — | — | CN | disclosed |
| EP-4437838-A1 | MODIFIED PLANT | Sun Pharmaceutical Industries Australia PTY Limited (AU) | 2024-10-02 | — | — | EP | disclosed |
| EP-3475417-B1 | COMPOSITIONS AND METHODS FOR MAKING BENZYLISOQUINOLINE ALKALOIDS, MORPHINAN ALKALOIDS, THEBAINE, AND DERIVATIVES THEREOF | ANTHEIA INC (US) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023069040-A1 | USE OF RETICULIN IMPURITY AS PURITY AND STABILITY SPECIFICATION IN MORPHINE AND MORPHINE EXTRACTS | FIDAN OZAN (TR) | 2023-04-27 | — | — | WO | disclosed |
| US-11427827-B2 | Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids | ANTHEIA, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022170385-A1 | PROCESS | SUN PHARMACEUTICAL INDUSTRIES AUSTRALIA PTY LIMITED (AU) | 2022-08-18 | — | — | WO | disclosed |
| EP-4041891-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING BENZYLISOQUINOLINE ALKALOIDS | River Stone Biotech ApS (DK) | 2022-08-17 | — | — | EP | disclosed |
| CN-109414489-B | NETIN-1 BINDING ANTIBODIES AND USES THEREOF | 埃缇健康公司D/B/A泽尔拜尔 | 2022-08-16 | — | — | CN | disclosed |
| US-20220205004-A1 | COMPOSITIONS AND METHODS FOR MAKING BENZYLISOQUINOLINE ALKALOIDS, MORPHINAN ALKALOIDS, THEBAINE, AND DERIVATIVES THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2022-06-30 | — | — | US | disclosed |
| WO-2022109194-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | ANTHEIA, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3947633-A1 | METHODS OF IMPROVING PRODUCTION OF MORPHINAN ALKALOIDS AND DERIVATIVES | Antheia, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125725-A1 | Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof | OPRD1, OPRM1, OPRK1 | DRD2 218/4885DRD1 205/4885BCHE 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.